Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Femasys Inc. FEMY
$0.77
-$0.02 (-2.51%)
На 18:05, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
10729234.00000000
-
week52high
2.97
-
week52low
0.57
-
Revenue
1206218
-
P/E TTM
-1
-
Beta
0.00000000
-
EPS
-0.99000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 04:00
Описание компании
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Maxim Group | Buy | 17 июн 2022 г. | |
| Chardan Capital | Buy | Buy | 25 мар 2022 г. |
| HC Wainwright & Co. | Buy | 24 мар 2022 г. | |
| JonesTrading | Buy | 13 июл 2021 г. | |
| Chardan Capital | Buy | 13 июл 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 21 окт 2022 г. |
| Chardan Capital | Buy | Buy | 11 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Thomas Christine E | A | 50000 | 50000 | 10 окт 2022 г. |
| Uzialko Edward R | A | 8500 | 8500 | 08 июн 2022 г. |
| Adams John Q JR | A | 8500 | 8500 | 08 июн 2022 г. |
| Larsen Charles | A | 8500 | 8500 | 08 июн 2022 г. |
| Morrissey Anne | A | 8500 | 8500 | 08 июн 2022 г. |
| Perrow Wendy | A | 25500 | 8500 | 08 июн 2022 г. |
| Dyett John | A | 8500 | 8500 | 08 июн 2022 г. |
| Elefant Dov | A | 100000 | 100000 | 28 февр 2022 г. |
| Perrow Wendy | A | 17000 | 17000 | 25 янв 2022 г. |
| Currie Daniel Scott | A | 20000 | 20000 | 25 янв 2022 г. |
Новостная лента
Femasys Inc. to Present at the Piper Sandler 34th Annual Healthcare Conference
GlobeNewsWire
21 ноя 2022 г. в 08:30
ATLANTA, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Kathy Lee-Sepsick, founder, president & chief executive officer, will present at the Piper Sandler 34th Annual Healthcare Conference being held November 29 through December 1, 2022 at the Lotte New York Palace Hotel in New York, NY.
Femasys Inc. to Participate in Upcoming January Investor Conferences
GlobeNewsWire
23 дек 2021 г. в 08:05
ATLANTA, Dec. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that the Company is participating in the LifeSci Partners 11th Annual Corporate Access Event, which will be held virtually from January 5-7, 2022, and the H.C. Wainwright BioConnect Conference, which will be held virtually from January 10-13, 2022.
Femasys Inc. to Present at The MedTech Conference
GlobeNewsWire
23 сент 2021 г. в 17:46
ATLANTA, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company aiming to meet women's needs worldwide by developing a suite of product candidates that include minimally invasive, in-office technologies for reproductive health, today announced that Kathy Lee-Sepsick, chairman, president and chief executive officer, will participate in a presentation at The MedTech Conference. Ms. Lee-Sepsick will speak on a panel in a session, entitled, “Early-Stage Medtech and Going Public.” The MedTech Conference, an annual event powered by AdvaMed, convenes the world's leaders in medical technology and will be held on a hybrid basis from September 21st-30th this year.
Femasys Inc. To Join the Russell Microcap® Index
GlobeNewsWire
20 сент 2021 г. в 16:05
ATLANTA, Sept. 20, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY) (“Femasys” or the “Company”), a biomedical company developing a suite of product candidates to transform women's healthcare with minimally invasive, non-surgical, in-office technologies, announced that the Company has been added to the Russell Microcap® Index today when the U.S. market opened. The Russell Microcap Index is widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. Approximately $10.6 trillion in assets are benchmarked against Russell's US indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
Femasys Inc. Announces the Appointment of Edward Evantash, M.D. as Chief Medical Officer
GlobeNewsWire
01 сент 2021 г. в 16:05
-- Industry veteran with over than two decades of experience in medical affairs to lead clinical and medical affairs at Femasys -- ATLANTA, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a biomedical company developing a suite of product candidates to transform women's healthcare with minimally invasive, non-surgical, in-office technologies, today announced the appointment of Edward G. Evantash, M.D., as chief medical officer. Dr. Evantash brings over two decades of industry experience in medical and clinical affairs to Femasys, having previously served as chief medical officer of Alydia Health and vice president of medical affairs at Hologic, Inc., both medical technology companies focused on women's healthcare. He will be responsible for providing leadership and direction for Femasys' pipeline of clinical development programs.